Ted Hupp

Next Generation Technologies for Drug Discovery In Cancer

Research in a Nutshell 

Cancer progression is driven in part by the mutation of genes that mediate immortality, angiogenesis, metastasis, changes in energy metabolism, and evasion of the immune system. P53 mutation is one of the most common genetic changes in cancer development that leads to a re-wiring and selective survival advantage to the developing cancer cell. This genetic re-wiring involves changes in the transciptome, the proteome, and the phenotype of the cell within a specific microenvironmental niche in vivo. The lab is using biophysical, biochemical, and proteomic approaches to develop novel molecular insights into clinically relevant cancer progression pathways; particularly cancers of unmet clinical need including oesophageal adenocarcinoma and sarcomas. Emerging therapeutic strategies being developed include drugging protein-protein interactions; biologics and immunotherapeutics; and proteogenomics platforms that define mutated neoantigen landscapes to facilitate cancer vaccine developments.

Research Programme

Contact

Ted.Hupp@ed.ac.uk

Collaborations

• Prof Mark Arends, University of Edinburgh
• Professor David Argyle, University of Edinburgh 
• Professor Kathryn Ball, University of Edinburgh 
• Professor Neil Carragher, University of Edinburgh
• Professor Rebecca Fitzgerald, Cambridge University
• Mr Graeme Grimes, University of Edinburgh
• Dr Larry Hayward, University of Edinburgh
• Dr Doug Houston, University of Edinburgh 
• Dr Rob O’Neill, University of Edinburgh
• Ian Overton, University of Edinburgh
• Professor Donald Salter, University of Edinburgh
• Professor Colin Semple, University of Edinburgh 
• Dr Borek Vojtesek, Masaryk Cancer Institute, Brno
• Professor Malcolm Walkinshaw, University of Edinburgh 
• Professor Nick Westwood, St Andrews University
• Professor Siva Umapathy, Indian Instutute for Science, Bangalore

Partners and Funders

• BBSRC
• Medical Research Scotland
• The Technology Strategy Board 
• British Council
• European Union Development Fund
• Wellcome Trust
• Cancer Research UK